Bruker Stock Might Rise From the Launch of Dimension Nexus AFM

Bruker Corporation BRKR recently launched the Dimension Nexus atomic force microscope (AFM) at the 2024 MRS Fall Meeting & Exhibit. Dimension Nexus comes with the latest-generation NanoScope 6 controller to deliver wider access to Bruker’s exclusive PeakForce Tapping technology and more than 50 AFM modes.The latest launch adds to the company’s industry-leading Dimension AFM product line. BRKR’s Likely Stock Trend Following the NewsSubsequent to the news, the share price of BRKR moved south 1.5% to $57.51 on Monday. Bruker’s Dimension AFM product line has had more than 4600 systems installed around the world. The company already has several Bruker AFMs in open-access user facilities, with the Dimension AFM product line installed in more than 4600 systems worldwide. Bruker is continuously putting efforts into bringing new technology to further support researchers in academia and industry. Henceforth, we expect the launch of Dimension Nexus AFM to motivate market sentiment toward BRKR stock in the upcoming days. Bruker currently has a market capitalization of $9.98 billion. In the fourth quarter of 2024, it had an earnings yield of 7.1% compared with the industry’s 5.6%. The company has a trailing four-quarter average earnings surprise of 5.32%.More Details on Bruker’s Dimension Nexus AFMDimension Nexus is an open-architecture system with low drift and noise that enables researchers to collect high-quality data for routine and custom experiments. The high-speed NanoScope 6 controller, combined with Bruker’s ScanAsyst technology, ensures unprecedented ease of use. Additionally, Dimension Nexus supports a wide array of unique modes, such as AFM-nDMA for viscoelastic measurements, PeakForce QNM for high-resolution quantitative mapping of mechanical properties and DataCube modes for hyperspectral imaging.The upgradability and enhanced ease of use of Dimension Nexus are critical developments that cater to the evolving needs of growing labs and multi-user facilities.Industry Prospects Favour BRKRPer a report from Coherent Market Insights, the atomic force microscope market is expected to reach $837.6 million by 2031 at a compound annual growth rate of 4.8% from 2024 to 2031.The growing semiconductor and electronics industry and the rising adoption of nanotechnology and material sciences are expected to act as key drivers for the market's growth.  Other Recent Developments by BrukerEarlier this month, Bruker announced a new technology, named EpicIF (Enhanced photobleaching in cyclic immunofluorescence), to further enhance the CellScape Precise Spatial Proteomics platform for highly multiplexed immunofluorescence (IF). The new technology is likely to enhance the CellScape platform by expanding antibody compatibility and doubling throughput while maintaining tissue integrity and lack of cross-reactivity. Image Source: Zacks Investment ResearchLast month, the company announced the formation of a new division, Bruker Spatial Biology, to offer the most diverse and comprehensive solutions for spatial biology. It operates coordination across three entities — the two businesses of NanoString Technologies and Canopy Biosciences, along with its subsidiary Bruker Spatial Genomics, Inc.BRKR’s Price PerformanceIn the past year, BRKR’s shares have risen 2.8% compared with the industry’s 21.8% growth. Zacks Rank and Key PicksBRKR currently carries a Zacks Rank #4 (Sell).Some better-ranked stocks in the broader medical space are ResMed RMD, Haemonetics HAE and Penumbra PEN. While ResMed sports a Zacks Rank #1 (Strong Buy) at present, Haemonetics and Penumbra carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.Estimates for ResMed’s fiscal 2025 EPS have risen 2.7% in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 32.1% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.Haemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. The company’s shares have risen 1.8% compared with the industry’s 23.1% growth in the past year. Estimates for HAE’s 2025 EPS have moved north 0.4% to $4.59 in the past 30 days. Estimates for Penumbra’s 2024 EPS have moved north 8.1% to $2.79 in the past 30 days. Shares of the company have surged 60.6% in the past year compared with the industry’s growth of 32.7%. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 10.54%.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ResMed Inc. (RMD): Free Stock Analysis Report Haemonetics Corporation (HAE): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks